

Acute Kidney Injury and Urinary Retention

This material was prepared by the IPRO QIN-QIO, a Quality Innovation Network-Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication # 12SOW-IPRO-QIN-T1-A5-23-1233



■ **Healthcentric
Advisors**
■ **Qlarant**

QIN-QIO
Quality Innovation Network -
Quality Improvement Organizations
CENTERS FOR MEDICARE & MEDICAID SERVICES
QUALITY IMPROVEMENT & INNOVATION GROUP

Acute Kidney Injury and Urinary Retention

Nadia Mujahid, MD, CMD, AGSF

Associate Prof. of Medicine

Warren Alpert Medical School of Brown University

September 19th, 2023

Disclosures

- Consultant CVS Caremark State of RI
- Member Pharmacy and Therapeutics Committee, Neighborhood Health Plan of RI

Objectives

- Review the definition and staging criteria for AKI
- Review the most common symptoms of AKI
- Review the most common causes of AKI
- Overview of treatment of AKI in SNF
- Overview of Urinary Retention

Definition

- Abrupt decrease in kidney function, resulting in the retention of urea and other nitrogenous waste products and in the dysregulation of extracellular volume and electrolytes

KDIGO Diagnostic criteria

- Increase in serum creatinine by ≥ 0.3 mg/dL within 48 hours

OR

- Increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior seven days

OR

- Urine volume < 0.5 mL/kg/hour for six hours

Staging of AKI

- Stage 1:
Increase in serum creatinine of ≥ 0.3 mg/dL or **1.5 - 1.9** times baseline
- Stage 2:
Increase in serum creatinine to **2 - 2.9** times baseline
- Stage 3:
Increase in serum creatinine to **≥ 3** times baseline
or **anuria for >12 hours**
or need for kidney replacement therapy

SYMPTOMS OF AKI

- Edema
- Hypertension
- Decreased urine output
- Change in baseline mental status (increased somnolence/lethargy)
- Incidental on routine lab work

Causes of AKI

PRE- RENAL 21%	RENAL			POST RENAL 10%
HYPOVOLEMIC STATE	TUBULAR/INTERSTITIAL* 45%	GLOMULAR	VASCULAR	OBSTRUCTION
-DEHYDRATION	-ISCHEMIA	PARANEOPLASTIC	VASCULITIS,	-Anywhere in the URINARY TRACT
-ACUTE HEMMORHAGE				
-DIARRHEA	-NEPHROTOXIC EXPOSURE*	DRUG INDUCED	SCLERODERMA,	-PROSTRATIC DISEASE SEC TO
HYPERVOLEMIC STATE		SYSTEMIC RHEUMATOLOGIC	ATHEROEMBOLIC	
-SYSTOLIC HEART FAILURE				-BPH/ CA/METASTATIC DISEASE
-ACUTELY DECOMPENSATED LIVER FAILURE			MALIGNANT HTN	

AKI Evaluation and Prevention in SNF

- New AKI vs. recovering from recent hospitalization
- Repeat labs in 1-3 days of SNF admission (baseline, follow trend)
- Repeat labs frequently if Serum Cr. Up trending, evaluate/hold nephrotoxic meds
- Add holding parameters to BP meds (to prevent hypotension/AKI)
- Low threshold to repeat stat labs if patient condition changes (quick, easy and cheap vs. ED evaluation)
- Repeat labs at least once a week if no symptoms

Treatment Depends on Cause of AKI

- Prerenal (hypovolemia), give IVFs, clysis, encourage PO
- Prerenal (hypervolemia), needs diuretics to decrease third spacing, closely follow clinical status and labs, might need ER/hospitalization
- Renal (tubular/interstitial), IVF, IVFs, IVFs, repeat labs frequently
- Hold all nephrotoxic meds (Ace-i/ARBs/diuretics, NSAIDs)
- Adjust doses of meds (Antibiotics/Insulin/Opiates except Dilaudid)
- Repeat labs to trend Serum Cr., Potassium, BUN
- If refractory to above and worsening labs, need ER evaluation

Emergency Kidney replacement therapy

- Pulmonary edema
- Hyperkalemia >6.5 mEq/L
- Hyperkalemia with cardiac conduction abnormalities, muscle weakness
- Hyperkalemia >5.5 mEq/L with ongoing tissue damage like rhabdomyolysis or ongoing potassium absorption like GIB
- Uremia with seizures or pericarditis, or an otherwise unexplained decline in mental status
- Severe Metabolic Acidosis (pH <7.1) and hypervolemia, unless acidosis can be rapidly resolve
- Acute poisoning

URINARY RETENTION

- Most common in older men with Prostatic disease and can lead to hydronephrosis
- Less common in females but can present sec to constipation, infection
- Straight catheterization for acute intervention
- Review medication history esp. for BPH meds (Tamsulosin, Finasteride), UI meds (Oxybutynin, Myrbetric) and resume
- Review new meds like opiates, Oxybutynin (known side effect)
- Start PVR, if >350 cc x 2, place Foley for bladder rest, TOV in 7 days
- Urology appointment, Renal US

Questions?

References

- KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl* 2012; 2:8.
- Kidney Disease: Improving Global Outcomes (KDIGO). Acute Kidney Injury Work Group. KDIGO clinical practice guidelines for acute kidney injury. *Kidney Int Suppl* 2012; 2:1.
- Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; 11:R31. Copyright © 2007 BioMed Central Ltd.